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Abstract
The down-regulation of miR-199 occurs in nearly all primary hepatocellular carcinomas (HCCs) and HCC cell lines in
comparison with normal liver. We exploited this miR-199 differential expression to develop a conditionally replication-
competent oncolytic adenovirus, Ad-199T, and achieve tumor-specific viral expression and replication. To this aim,
we introduced four copies of miR-199 target sites within the 3’ UTR of E1A gene, essential for viral replication. As
consequence, E1A expression from Ad-199T virus was tightly regulated both at RNA and protein levels in HCC
derived cell lines, and replication controlled by the level of miR-199 expression. Various approaches were used to
asses in vivo properties of Ad-199T. Ad-199T replication was inhibited in normal, miR-199 positive, liver parenchyma,
thus resulting in reduced hepatotoxicity. Conversely, the intrahepatic delivery of Ad-199T in newborn mice led to virus
replication and fast removal of implanted HepG2 liver cancer cells. The ability of Ad-199T to control tumor growth
was also shown in a subcutaneous xenograft model in nude mice and in HCCs arising in immune-competent mice. In
summary, we developed a novel oncolytic adenovirus, Ad-199T, which could demonstrate a therapeutic potential
against liver cancer without causing significant hepatotoxicity.
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Introduction
Oncolytic viruses have been proposed for cancer therapy,
since they can be engineered to potentially deliver their
cytocidal effect to tumor cells [1,2]. Among them, adenoviruses
were widely used as oncolytic viral agents in cancer therapy,
as they possess an inherent potential to kill the cells that
sustain their replication [3]. However, to restrict cytocidal effect
to tumor cells, their replication had to be tightly controlled in
normal cells. Hence, conditionally replicative adenoviruses
(CRAds) have been developed to restrict viral replication to
target cancerous tissues and inhibit replication in normal
healthy cells. This has been attempted by exploiting loss-of-
function mutations in E1B viral sequences [4], or linking genes
E1A/E1B to cancer-specific promoters, such as the telomerase
or prostate-specific rat probasin promoters or the human
prostate-specific enhancer/promoter [5,6,7]. Additional
approaches have also been explored for specific targeting
viruses to cancer cells, for example through the introduction of
T-cell receptors specific for tumor-specific antigens [8].
More recently, a strategy based on endogenous microRNAs
(miRNAs) has been explored to control viral replication [9].
miRNAs are small, non-coding RNA molecules of 20–24 bp
that can regulate gene expression at the post-transcriptional
level by binding to target transcripts in a sequence-specific
manner [10]. These small molecules play a critical role in many
cellular processes and several examples of aberrantly
regulated miRNAs in human cancer have been reported [11].
Among all, miRNAs expression profiling in hepatocellular
carcinomas (HCCs) revealed the existence of differential
patterns between tumor tissues and normal liver. In particular,
miR-199 was reported to be consistently down-regulated in
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HCC [12]. The involvement of miR-199 in the pathogenesis of
HCC was linked to the abnormal regulation of multiple target
genes, such as mTOR, c-Met, HIF-1α and CD44 [13,14,15,16].
Here, we took advantage of this information to produce a new
type of CRAd able to replicate only in cells lacking miR-199,
with the aim of making viral replication and cytolytic effect
specifically selective for HCC cells.
HCC, the fifth most frequent neoplasm and the third leading
cause of cancer-related deaths worldwide [17], carries a
generally poor prognosis. Complete tumor removal represents
the only long-term cure. However, partial hepatectomy can be
undertaken in less than 15-30% of patients due to the extent of
underlying cirrhosis and, among patients who undergo tumor
resection, up to 75% of patients will develop intra-hepatic
recurrences within 5 years [18]. When possible, complete
hepatectomy and orthotopic liver transplantation (OLT)
represents the therapy of choice for patients with significant
cirrhosis and limited tumor burden [19,20,21]. In patients who
are not candidates for liver transplantation or resection, the
most common therapy is transcatheter arterial chemo-
embolization (TACE) [22], whose impact on clinical outcome
remains unclear. The use of systemic chemotherapy has been
attempted but HCC is minimally responsive. More recently, the
multi-kinase inhibitor sorafenib, able to target multiple
pathways and blocking RAF/MEK/ERK signaling at the level of
raf-kinase as well as by inhibiting vascular endothelial growth
factor receptor (VEGFR) and platelet-derived growth factor
receptor beta (PDGFR-beta), was shown to improve survival
and increase time to disease progression in advanced HCCs
[23]. In spite of these efforts, with the exception of early and
very early tumor stages, HCC remains an incurable disease
and new more effective and less toxic therapeutic strategies
are needed.
Materials and Methods
Ethics statement
The study was carried out in strict accordance with the
Guidelines for the Care and Use of Laboratory Animals of the
Italian Ministry of Health. Protocol has been approved by the
Comitato Etico di Ateneo per la Sperimentazione Animale
(C.E.A.S.A.) of the University of Ferrara (protocol n. 9752).
Animals were sacrificed under inhalational anesthesia with
isoflurane to minimize suffering.
Vectors construction
Four copies of a 22 bp DNA segment complementary to
miR199 were inserted within the 3’-untraslated region (3’-UTR)
of the E1A gene, which is essential for adenoviral replication.
The oligonucleotides containing the sequences (1) 5’-CTA GAT
AAC CAA TGT GCA GAC TAC TGT ccT AAC CAA TGT GCA
GAC TAC TGT ccT AAC CAA TGT GCA GAC TAC TGT ccT
AAC CAA TGT GCA GAC TAC TGT ccT-3’ and (2) 5’-CTA
Gag gAC AGT AGT CTG CAC ATT GGT Tag gAC AGT AGT
CTG CAC ATT GGT Tag gAC AGT AGT CTG CAC ATT GGT
Tag gAC AGT AGT CTG CAC ATT GGT TAT-3’, were
synthesized at IDT (Integrated DNA Technologies Inc.,
Coralville, Iowa, USA), self-annealed and phosphorylated using
a polynucleotide kinase (Roche Applied Science, Indianapolis,
USA). To confirm its functional activity, we first cloned the
miR-199 artificial target sequence downstream of the firefly
luciferase reporter gene at the XbaI restriction site within the
pGL3 vector (Promega, Madison, WI, USA), to generate
pGL3/199T vector. This vector was transfected into the
hepatocarcinoma Hep3B cells together with either miR-199 or
scrambled oligos. As expected, the luciferase activity was
significantly decreased only in samples co-transfected with
miR-199 (p value = 0.007), thus proving the functional
interaction between miR-199 and the artificial target sequences
(Figure S1). To produce the adenoviral vector, several steps
were employed, as depicted in Figure S2. The adenoviral
backbone was from pAdCMV-V5-Dest (Gateway technology,
Invitrogen, Carlsbad, CA, USA), a replication-defective
adenovirus that lacks the E1A/E1B locus. The pShuttle/K
vector, containing a subgenomic adenovirus type 5 (Ad5)
fragment, was the source for the wild type E1A/E1B gene. The
E1A/E1B DNA segment included an ectopic translation
initiation site in the wrong reading frame within the 5’ UTR of
E1A mRNA, to uniformly reduce E1A protein levels in all cell
types, and a MluI restriction site within the 3’ UTR of the E1A
gene, was previously reported [9]. The MluI site was used for
introducing the miR-199 target segment, originally cloned into
the pGL3/199T (as described above). The non-replicative
adenovirus Ad-Null-Control (ADV-001) was provided as a
premade Recombinant Adenovirus from Cell Biolabs (Cell
Biolabs, Inc, San Diego, CA).
To produce the pIRES-miR199 plasmid, a 650 bp region of
human genomic DNA including pre-miR and mature miRNA
sequence was amplified from 293 cells with the primers
miR199NheI_Fwd (5’-GCT AGC GAC CCC CAA AGA GTC
AGA CA-3’) and miR199NheI_Rev (5’-GCT AGC CCA CCC
TCT TAG ATG CCT CA-3’). The fragment was cloned into a
pIRESneo2 plasmid at the NheI restriction site and controlled
by sequencing. The pIRES-Luc plasmid was constructed
cloning the Luciferase gene (obtained from a pGL3-Control
vector, Promega, Madison, WI, USA) in a pIRESneo2
backbone at a NheI restriction site.
Cell culture
The hepatocellular carcinoma cell lines HepG2 (ATCC
HB-8065) and Hep3B (ATCC HB-8064) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA). The
human embryonic kidney cells, 293FT transformed with the
SV40 large T antigen were obtained from Invitrogen (Carlsbad,
CA, USA). Cell lines were propagated and maintained in
Dulbecco’s Modified Iscove’s Medium (IMDM) supplemented
with 10% fetal bovine serum (FBS), 0.1% Gentamycin and 1%
L-glutamine (Sigma, St Louis, MO).
Luciferase Assay
Luciferase expression was analyzed using the Dual
Luciferase Reporter Assay (Promega, Madison, WI, USA),
following the manufacturer’s protocol. Hep3B cells were plated
at a density of 7x104 cells/well in a 24 wells plate. Transfections
were performed with 400 ng of pGL3/199T vector (firefly
luciferase) and normalized by co-transfecting 40 ng of pRL-TK
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(renilla luciferase) vector. The pre-miR-199a-3p miRNA
precursor (Ambion Applied Biosystems, Grand Island, NY,
USA) or the control oligonucleotide (AM17111, Ambion Applied
Biosystems, Grand Island, NY, USA) were co-transfected at a
concentration of 100 nM.
HepG2 derived cell lines
To produce stable cell clones expressing miR199, HepG2
cells were transfected with 2 µg of a miR-199 expressing
plasmid, pIRES-miR199, using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA). To produce stable cell clones expressing the
firefly Luciferase reporter gene, HepG2 cells were transfected
with 2 µg of a Luciferase expressing vector, pIRES-Luc. After
24 hours, cells were diluted into T75 flasks and subjected to
selection using 700 µg/ml G418 (Roche Applied Science,
Indianapolis, USA) for 2 weeks.
Real-Time RT-PCR analysis
The expression of mature miRNAs was quantified by the
Taqman MicroRNA Assays (Applied Biosystems, Grand Island,
NY, USA). Total RNA was isolated from cells using Trizol
reagent (Invitrogen). Reverse transcription reaction was done
starting from 5ng of total RNA. Real-Time PCR was performed
using the standard Taqman MicroRNA Assay protocol on the
iCycler iQ Real-Time PCR Detection System (Biorad). The
reactions were incubated at 95°C for 10 min followed by 40
cycles of 95°C for 15s and 60°C for 1 min. The ∆∆Ct method
for relative quantification of gene expression was used to
determine miRNA expression levels. Fold change was
generated using the equation 2-∆∆Ct. Each sample was analyzed
in triplicate. To normalize the relative abundance of miRNA
was used the Taqman Assays for U6 RNA (RNU6B, Applied
Biosystems, Grand Island, NY, USA).
Production of Recombinant Adenoviruses
Recombinant adenovirus encoding the E1A/199T/E1B region
and the IRES-EGFP cassette expressing the green fluorescent
protein was produced using the in vitro recombination
techniques. Briefly, the E1A/E1B region for the adenovirus
genome (GenBank, accession number AC_000008) was
amplified by PCR from the plasmid pShuttle/K and subcloned
into a pGEM-T vector (Promega, Madison, WI, USA). The
fidelity of the clone was verified by sequencing. For the
construction of the adenoviral control vector, the EcoRI
E1A/E1B fragment was excised from the plasmid
pGEM_E1A/E1B and cloned into the EcoRI site of a modified
pENTR11 vector (Invitrogen, Carlsbad, CA, USA) containing an
IRES/EGFP sequence, to generate the plasmid pENTR_E1A/
E1B. For the construction of the adenoviral miR-199 dependent
plasmid, an MluI fragment containing the microRNA-199 target
sequence was amplified by PCR from the plasmid pGL3-199T
and inserted into a MluI site located in the 3’ UTR of E1A
sequence in the vector pENTR_E1A/E1B, to generate
pENTR_E1A/199T/E1B. To construct recombinant plasmids,
the ViraPower Adenoviral Gateway Expression System was
used, according to the manufacturer’s instructions (Invitrogen,
Carlsbad, CA, USA). The recombinant adenoviral plasmids
obtained, pAd-199T and pAd-Control, were linearized with PacI
restriction enzyme and then transfected into 293FT cells using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The viral
progeny were packaged into 293FT cells and purified using
PEG-it Virus Precipitation Solution (System Bioscences,
Mountain View, CA), according to manufacturer’s instructions.
Titration of Recombinant Adenoviruses
To determine the titer of Ad-199T and Ad-Control viruses,
7x104 HepG2 cells were seeded in a 24 well plate; after 24
hours, cells were infected with 1 microliter of either viruses.
One day after infection, cells were harvested and total genomic
DNA was purified by QIAmp DNA Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. 50ng of
genomic DNA was analyzed by quantitative Real-Time PCR,
using EVA green (Biotium Inc, Hayward, CA, USA) and primers
specific for wild type Ad5 sequences: wtAd5Fwd, 5′- CGC ATA
CGA GCA GAC GGT GAA C-3′; wtAd5Rev, 5′- GCA CTA TAA
GGA ACA GCT GCG CC -3′. PCR was performed by initial
denaturation at 95°C for 15min followed by 40 cycles of 30s at
95°C, 30s at 58°C and 30s at 72°C. A standard curve was
generated by using serial dilutions of the plasmid pAd-Control
DNA (from 10ng to 100fg) spiked in 50 ng of HepG2 non
infected genomic DNA. The number of viral infectious units
(I.U.) was determined comparing the threshold cycle (Ct)
values of each sample with those of standard samples.
Fluorescence was measured by using a Biorad-Chromo4
thermal cycler real-time PCR instrument.
Assessment of Viral Replication
To assess viral replication, adenoviral DNA in infected cells
was quantified by Real-Time PCR, using EVA green (Biotium
Inc, Hayward, CA, USA) and primers wtAd5Fwd and
wtAd5Rev, specific for wild type Ad5. PCR was performed by
initial denaturation at 95°C for 15min followed by 40 cycles of
30s at 95°C, 30s at 58°C and 30s at 72°C. Fluorescence was
measured by using a Biorad-Chromo4 thermal cycler real-time
PCR instrument. Human or mouse β-actin gene was used to
normalize data. Primers were as follows: Hβ-
actinDNA2810Fwd, 5’-AGC TGT CAC ATC CAG GGT CC -3’;
Hβ-actinDNA2960Rev 5’- TCA TAC TCC TGC TTG CTG ATC
C -3’, Mβ-actinDNAFwd, 5’- AAG GGT TAC CCG GGA TAC
TG-3’; Mβ-actinDNARev, 5’- TGT TAC CAA CTG GGA CGA
CA-3’.
Analytical PCR on genomic DNA
Genomic DNA from infected cells and from frozen tissues
was extracted with the QIAmp DNA Mini Kit (Qiagen, Hilden,
Germany) according to manufacturer’s instructions. Analytical
PCR, was performed by initial denaturation at 95°C for 15min
followed by 30 cycles of 30s at 95°C, 30s at the specific
annealing temperature and 30s at 72°C. Viral DNA was
analyzed using primers wtAd5Fwd and wtAd5Rev, specific for
wild type Ad5. For human TPEF detection, primers were as
follows: TPEF-Fwd, 5'-CTC AGC GGA CGA CCC TCT CGC
TCC G-3'; TPEF-Rev, 5'-GGC GGC GGC GGT GGC AGT
GG-3'. Human or mouse β-actin gene was used to normalize
data.
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Adenovirus E1A gene expression
Quantification of Adenovirus E1A mRNA expression was
carried out using EVA Green-based Real-Time PCR detection.
Total RNA was extracted from a portion of frozen liver tissues
after homogenization, with Trizol reagent (Invitrogen) according
to manufacturer’s instructions. For quantitative PCR analysis,
200ng of purified RNA were retro-transcribed and 5 µl of cDNA
was used for the PCR reaction using EVA Green (Biotium Inc,
Hayward, CA, USA). All reactions were carried out in a 20
microliters. Primers were as follows: E1A_1325Fwd, 5’-CCC
GAC ATC ACC TGT GTC TA-3’ and E1A_1465Rev, 5’-GAT
ACA TTC CAC AGC CTG GC-3’; 18sFwd, 5′-AGC AGC CGC
GGT AAT TCC AGC T-3′ and 18sRev, 5′-CGG GAC ACT CAG
CTA AGA GCA TC-3′. PCR was performed by initial
denaturation at 95°C for 15min followed by 40 cycles of 30s at
95°C, 30s at 58°C and 30s at 72°C. The threshold cycle (Ct)
values of each sample were used in the post-PCR data
analysis. Each sample was analyzed in triplicate. E1A
expression levels were normalized against ribosomal RNA
18S, as housekeeping gene. Fluorescence measurements
were completed using a Biorad-Chromo4 thermal cycler real-
time PCR instrument.
Western Blot analysis
To evaluate the expression of adenoviral E1A protein, cells
were seeded in 24-well plates at a density of 7×104 cells/well,
cultured for 24 h, and infected with 1×106 I.U of Ad-Control or
Ad-199T. Two days later, cells were harvested and lysed by
using RIPA lysis buffer (150 mM NaCl, 0.1% SDS, 0.5%
sodium deoxycholate, 1% NP-40) (Sigma, St Louis, MO) with
complete protease inhibitor cocktails (Sigma, St Louis, MO).
Homogenates were then centrifuged at 13000 rpm for fifteen
minutes at 4°C and supernatants were collected and analyzed
by Western blot to assess E1A protein expression with a
polyclonal anti-E1A antibody (sc-430, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Digital images of
autoradiographies were acquired with Fluor-S MultiImager
(BioRad) and band signals were acquired in the linear range of
the scanner using the densitometric module of the software
Quantity One (BioRad). After autoradiography acquisition, the
membranes were reprobed for 1 h at room temperature with
anti-β-tubulin polyclonal antibody H-235 (sc-9104, Santa Cruz
Biotechnology, Santa Cruz, CA) diluted 1:1000 as
housekeeping gene.
Immunohistochemical analysis
A rabbit polyclonal lgG anti-phospho-H2A.X (Upstate, Cell
Signaling Solutions, NY, USA) recognizing the phosphorylated
Ser 139 of histone H2A.X was used as primary antibody for
immunohistochemistry. Immunoreactivity was revealed with the
HRP (Horse-Radish-Peroxidase) EnVision system (DAKO,
Denmark), and DAB (diaminobenzidine) as chromogen (Sigma,
St Louis, USA). Primary antibody was incubated over night at
1:200 dilution. The secondary antibody was incubated 1 hour at
room temperature. Mounted slides were examined by light
microscopy and immunoreactivity assessed by using a 3-grade
system: 0, no staining; +, minimal staining and ++, uniform or
intense staining.
In vivo mouse experiments
For the treatment of liver cancer, the miR-221 transgenic
strain (TG221), which is predisposed to the development of
liver cancer, was employed [24]. This mouse strain has an
increased susceptibility to the carcinogen diethylnitrosammine
(DEN) and tumors exhibit a miRNA profile similar to human
HCC, including the down-regulation of miR-199. The mice were
maintained in a vented cabinet at 25°C with 12-hour light-dark
cycle and provided food and water ad libitum. To facilitate
tumor development, DEN was injected intra-peritoneally (7.5
mg/kg body weight) at day 10 after birth. Virus injections into
the tail vein were performed by using 1x108 I.U. of Ad-199T or
control virus. All mice were sacrificed at the end of month 5,
subjected to autopsy. Livers were partly fixed in 10% formalin
for histopathological investiagations and partly frozen in liquid
nitrogen for molecular studies. Liver DNA was isolated using
the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) and RNA
by using with Trizol reagent (Invitrogen), according to the
manufacturers’ procedures. For “nude” mice experiments, mice
were maintained in a vented cabinet at 30°C with 12-hour light-
dark cycle and provided food and water ad libitum. Hep3B
tumor xenografts were established by subcutaneous
inoculation of 5x106 cells into the right flank of 4 week-old CD-1
nude mice (Charles River Laboratories International,
Wilmington, MA), maintained at pathogen-free conditions.
When tumors reached 5 to 15 mm3, the animals were
randomized in 2 groups (n=6 mice per group) and treated with
either phosphate buffered saline (PBS) solution or 5x108 I.U.
Ad-199T virus (diluted into PBS) by intra-tumoral injection. The
injections were performed once every other day for a total of
six injections. Tumors were measured every 2 days and
volume was calculated by the formula (length x width2)/2.
Animals were sacrificed when the tumor volume reached 1,000
mm3, which was also the end-point of the overall survival
analysis.
In Vivo Imaging System (IVIS)
In vivo bioluminescent imaging was performed with a ultra-
low noise, high sensitivity cooled CCD camera, mounted on a
light tight imaging chamber (IVIS 100 SystemTM, Xenogen,
Roissy, France). Tracking, monitoring and quantification of
signals were controlled by the acquisition and analysis software
Living ImageH (Xenogen Corp, Alameda, CA). D-luciferin was
injected intra-peritoneum (i.p.) at a dose of 150 mg/kg body
weight (30 mg/ml luciferin) to anesthetized (1–3% isoflurane)
animals 15 minutes before image acquisition. Anesthetized
mice were then placed in the IVISTM Imaging System and
imaged. Three-four mice were imaged at each time. Regions of
interest from displayed images were identified around the
tumor sites and were quantified as total photon counts or
photons/s using the Living ImageH software (Xenogen Corp,
Alameda, CA).
Statistical analysis
Statistical significance of groups similarity was resolved
using a 2-tails Student’s t test. A p-value threshold < 0.05 was
considered significant. When appropriate, group value was
expressed as mean ± standard deviation (SD). Survival
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analysis was performed by using a Kaplan-Meier plot, and
significance assessed by the log rank test.
Results
Construction of a replication selective adenovirus
The rationale of the work was based on the differential
expression of miR-199 between normal versus cancer liver
cells and in particular on the basis that miR-199 is down-
regulated in human hepatocellular carcinoma [12]. To develop
a conditionally replication-competent oncolytic adenovirus
(CRAd) under miR-199 control, named Ad-199T, four copies of
a 22 bp DNA segment complementary to human and mouse
miR-199, were inserted within the 3’-untraslated region (3’-
UTR) of the E1A gene, essential for adenoviral replication. For
the construction of the adenoviral vectors, the adenoviral
backbone was from pAdCMV-V5-Dest (Invitrogen), which lacks
the E1A/E1B locus. The E1A/E1B sequences were obtained
from the pShuttle/K vector [9] by PCR amplification using
primers containing EcoRI sites, and introduced within the
EcoRI site of the intermediate vector pENTR-IRES-EGFP. A
replicative control adenovirus, Ad-Control, without miR-199
target sequences, was also developed (Figure 1). Details of
vectors construction are described in Materials and Methods
and in Figure S2. The titer of the produced adenoviruses were
as follows: 6.24x1010 I.U/ml pAd-199T and 1.95x1010 I.U/ml
pAd-Control.
Ad-199T replication is microRNA-dependent
To verify if miR-199 could regulate viral replication in vitro,
Ad-199T and Ad-Control were used to infect two different cell
lines: (1) HepG2, derived from human liver carcinoma and not
expressing miR-199; (2) HepG2/199, which derives from
HepG2 cells engineered to constitutively express miR-199a
Figure 1.  Description of the conditionally replication-competent oncolytic Adenovirus.  (A) Schematic illustration of
Adenovirus type 5 genome: the viral early and late genes and the Inverted Terminal Repeat (ITR) are indicated. (B) TheAd-Control
viral genome encloses the E1A/E1B genes and the IRES-EGFP expression cassette. (C) The Ad-199T viral genome contains a
specific sequence complementary to microRNA 199a-3p (miR-199 target) in the 3’ untranslated region of the E1A gene. (D) The
miR-199 target sequence is made of 4 copies of a 22bp DNA segment complementary to the mature miRNA.
doi: 10.1371/journal.pone.0073964.g001
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(Figure S3). To this purpose, 7×104 cells of each cell line were
seeded and infected with 1x106 I.U. of Ad-199T or with 1x106
I.U. of Ad-Control. The cells were harvested after 24, 48, 72, 96
and 120 hours to assess E1A viral gene expression together
with viral replication. The inhibition of E1A mRNA and protein
was demonstrated in miR-199 expressing HepG2 cells, while
E1A normal expression could be detected in HepG2 wild type
cells (Figure 2A-B). Correspondingly, the active viral replication
occurred for both viruses in HepG2 cells, while in HepG2/199
cells only Ad-Control could replicate and Ad-199T virus was
inhibited (Figure 3). These results established that viral
replication of Ad-199T was indeed miR-199-dependent in vitro.
To assess replication properties of Ad-199T in vivo, we tested
its ability to replicate in the liver of B6D2 wild type mice, where
miR-199 is constitutively expressed. To this purpose, 1x108 I.U.
of Ad-199T virus or 1x108 I.U. of Ad-Control virus were intra-
hepatically injected into 3 days old mice. At 72 hours after
infection, livers were collected and genomic DNA was
extracted as described in methods section. Viral DNA was
quantified by qPCR using primers specific for Adeno-5 wild
type sequence. The results demonstrated that the viral DNA
was significantly reduced in livers of mice infected with
Ad-199T virus in comparison with livers of mice treated with
Ad-Control (p-value = 0.0442) (Figure 4). Effect of viral
treatment on normal liver was also evaluated by histological
analyses. No significant histopathological changes were
detectable in Ad-199T treated livers, with a well preserved liver
architecture and nearly absent necrotic damage. On the other
side, Ad-Control induced significant hepatotoxicity: Ad-Control
treated livers were characterized by a poorly preserved liver
architecture, with portal tracts barely distinguishable due to
hepatocyte swelling. Hepatocytes enlargement was associated
with nuclear dissolution, indicative of necrotic damage. Large
areas with hepatocytes with macro- and micro-vesicles were
visible. In addition, immuno-staining for the phosphorylated
form of the histone H2AX, an early marker of double strand
breaks, displayed a nearly complete staining of the nuclei
following infection of Ad-Control, but absent in Ad-199T-
infected livers (Figure S4). These results demonstrated that
Ad-Control replicates efficiently in normal liver cells, inducing
hepatotoxicity, while miR-199 could control Ad-199T lytic cycle
in normal hepatocytes in vivo.
Ad-199T can eliminate tumor cells with same efficiency
of Ad-Control virus
After proving that Ad-199T virus can poorly replicate in
normal liver cells, we investigated whether this same virus
could instead replicate and have a cytocydal effect in tumor
cells in vivo. To this aim, 2x106 HepLuc cells, HepG2 cells
engineered to express the Firefly luciferase reporter gene
(Figure S5), were implanted into the liver of 3 days old B6D2
wild type mice. To verify the presence of the HepLuc cells into
the target liver tissue, the mice were examined at the In Vivo
Imaging System (IVIS) Spectrum and light emission measured
two hours after cell implantation. The detection of a strong light
emission signal established the presence of implanted cells in
the liver of all animals (Figure 5A). After 24 hours, three
experimental groups, consisting of six mice each, were defined:
one was infected intra-hepatically with 1x108 I.U. of Ad-199T
virus; the second with 1x108 I.U. of Ad-Control virus; the third
group was not infected and used as control to monitor HepLuc
cells luminescence during the experimental time-frame. Mice
were monitored at the IVIS at 24, 48 and 72 hours after virus
infection. Non infected animals exhibited a strong signal at 24
hours, which progressively and gradually decreased at 48 and
72 hours, indicating the presence of the cells during all the
observation time points. Conversely, in the virally infected
animals the signal decreased more rapidly, to almost
completely disappear at 72 hours. These results suggested
that the implanted tumor cells were likely eliminated due to
active viral replication by either Ad-Control or Ad-199T (Figure
5B-D). A quantitative photon counting analysis of the region-of-
interest showed a highly significant decrease (p-value <0.05) of
luminescence in mice infected with the Ad-Control or the
Ad-199T viruses vs. uninfected control animals (Figure 5E). At
72 hours, HepLuc cells derived liver tumor mass was evident in
correspondence of the signal detected at the IVIS luminometer
in non-infected animals. Conversely, in mice injected with both
viruses, there was evidence of significant reduction or loss of
liver tumor masses, consistent with the absence of luminous
signal (Figure S6). These data indicated that both Ad-199T and
Ad-Control viruses could replicate in vivo and eliminate the
implanted tumor cells. To exclude that antitumor effect was
prevalently induced by an immune response against
adenovirus antigens, we included a group of animals injected
with a replication-defective adenovirus (Figure S8). The
experiment showed that, while an immune response to virus
antigens was also involved in tumor cells removal, the lytic
cycle of the virus was still producing the fastest removal of
tumor cells. The difference of light emission between cells
infected with replication-competent versus replication-defective
viruses remained statistically significant at all time-points.
To assess viral replication and confirm that Ad-199T
replication was restricted to cancer cells, HepLuc cells were
implanted into the liver of a new group of B6D2 wild type mice
and treated with 1x108 I.U. of Ad-199T virus after 24 hours. The
animals were sacrificed at 24 and 48 hours after the treatment
and livers were collected for DNA analyses: the presence of
human HepLuc cells derived DNA was confirmed in the tumors
by analytical PCR (Figure S7) and then the presence of viral
DNA was assessed both in the tumors and in the surrounding
normal parenchima. The presence of viral DNA was detected
only in tumor tissues, indicating that an active viral replication
was occurring in neoplastic tissue but not in normal liver
(Figure 6). The result confirms that the replication of Ad-199T
virus was significantly suppressed in normal liver compared to
tumor cells.
Ad-199T has antitumor efficacy in a HCC implanted
tumor model
The antitumor potential of Ad-199T virus was evaluated in a
subcutaneous xenograft of Hep3B tumor cells. Ad-199T
replication in Hep3B cells was preliminarily verified in vitro
(Figure S9). Then, nude mice bearing Hep3B tumors were
intra-tumorally treated three times a week for two weeks either
with phosphate buffer or with Ad-199T virus (5x108 I.U. each
miR-199-Dependent Oncolytic Adenovirus
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injection). The group of Ad-199T treated mice exhibited a
kinetic of tumor growth significantly reduced (Figure 7A), which
resulted in an increased survival (Figure 7B).
Ad-199T can control liver tumorigenicity
After demonstrating the oncolytic activity of Ad-199T in a
subcutaneous xenograft tumor model, we aimed at verifying
whether Ad-199T could control liver primary tumors. We
employed a transgenic mouse model over-expressing
microRNA-221 (TG221) [24], which was shown to be highly
predisposed to the development of liver tumors and, most
importantly, tumors exhibited a miRNA pattern similar to human
HCC. Useful for the objective of this study, we previously
showed that miR-199 is down-regulated in liver tumors arising
in this model. Three experimental groups, consisting of four
mice each, were defined: one group was infected with
Ad-199T, at day 60 and 135 after DEN injection, each time with
1x108 I.U. of Ad-199T virus, through injection into the tail vein.
The other groups were controls: one was infected with a non-
replicative adenovirus (Ad NR), to assess the effect of an
eventual immune response against liver cells infected by an
adenovirus, the other group was a non-infected control, to
Figure 2.  E1A expression is miR-199 dependent.  To assess the expression of E1A in presence or absence of miR-199, 7×104
cells of HepG2 and HepG2/199 cell lines were seeded and infected with 1x106 I.U. of Ad-199T or with 1x106 I.U. of Ad-Control and
harvested after 48 hours. E1A levels were evaluated by quantitative PCR analysis (A) and by Western Blot (B). In HepG2, E1A
mRNA was expressed following infection by both viruses; conversely, in HepG2/199 the E1A mRNA levels were significantly lower
in AD-199T infected cells compared to Ad-Control infected cells. P-values of the comparisons are shown. The same results were
obtained at the protein level. This evidence confirms that miR-199, constitutively expressed in HepG2/199 cells, can control E1A
expression by targeting the homologous sequences places downstream of the adenoviral E1A gene.
doi: 10.1371/journal.pone.0073964.g002
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assess the effect of DEN alone. All mice were sacrificed at 5
months of age. Livers displayed macroscopically evident tumor
masses in all animals; however, the Ad-199T infected mice
displayed a reduced liver tumor burden, either by visual
inspection and by total liver weights in comparison with controls
(Figure 8A-C). Histologic analyses confirmed that the number
of tumor nodules was significantly lower in mice treated with
Ad-199T (Figure 8D).
To assess if these findings were related to miR-199
expression, we analyzed the level of the miRNA in normal liver
and tumor tissues. Quantitative PCR revealed that miR-199
was down-regulated in tumors in comparison with normal liver
(p value = 0.0146) (Figure 8E). Furthermore, to verify whether
Ad-199T could more efficiently replicate in tumor tissues, we
injected i.v. Ad-199T (1x108 I.U.) into the tail vein of 5-months
old mice-bearing tumors. After 48 h, mice were sacrificed and
viral DNA quantified by quantitative PCR in normal (4 biopsies)
and tumor tissues (6 different nodules). The level of Ad-199T
DNA was 2-3-fold higher in tumor nodules than in normal liver
tissues (Figure 8F). Taken together, these findings can be
interpreted as evidence that Ad-199T could replicate more
efficiently in tumor tissues, where it can produce cytolysis, and
this property was most likely miR-199-dependent.
Figure 3.  miR-199 controls Ad-199T replication in vitro.  (A-B) To asses viral replication in absence and in presence of
miR-199, HepG2 and HepG2/199 cell lines were infected with Ad-199T or Ad-Control adenoviruses. A progressive accumulation of
viral DNA, indicated as fold change copies of Adeno DNA referred the lower level of Adenovirus DNA copies, indicates that active
viral replication is efficiently occurring in both cell lines infected with Ad-Control virus. A progressive accumulation of viral DNA in the
HepG2 cells infected with Ad-199T indicates that active viral replication is efficiently occurring in this cell line; on the contrary, in
HepG2/199 cells infected with Ad-199T the viral DNA did not increase over time, confirming that the virus replication was inhibited
by the presence of miR-199. P-values of the comparisons are shown.
doi: 10.1371/journal.pone.0073964.g003
miR-199-Dependent Oncolytic Adenovirus
PLOS ONE | www.plosone.org 8 September 2013 | Volume 8 | Issue 9 | e73964
Discussion
This work establishes that the presence of miR-199 target
sites within the 3’ UTR of E1A gene represents a strategy to
generate recombinant adenoviruses with significant oncolytic
activity against liver cancer, which exhibits low level of
miR-199, coupled with reduced hepatoxicity.
Oncolytic virotherapy emerged as a promising experimental
approach to fight cancer. Oncolytic Ad5-based viruses
demonstrated efficacy and safety in preclinical [25,26] and
clinical trials [27,28,29,30]. The possibility to improve
therapeutic efficacy by combining adenoviral virotherapy and
chemo or radiation therapy to eradicate malignant glioma
produced highly encouraging results with evidence complete
tumor eradication in animal models [31,32,33].
For safe and effective gene therapy, target tissue-restricted
virus expression is desirable. Conditionally Replicative
Adenoviruses (CRAds) specifically aimed at killing tumor cells
while sparing normal cells have been developed as new agents
for cancer therapy [4,34,35]. Various methods have been used
to achieve a selective expression. These approaches included
the use of tumor-specific promoters to drive E1A gene
expression [7,36,37,38] or the E1B deletion, which restricts the
oncolytic activity to p53-defective tumor cells. Among these,
ONYX-015 was the first to be tested in clinical trials, revealing
itself as a well-tolerated and safe tool and a promising
therapeutic agent in cancer [39]. Moreover, its use in
combination with standard chemotherapy was demonstrated to
increase antitumor activity [40]. By using a very similar virus,
H101, a multicenter randomized phase 3 clinical trial showed
that the combination therapy yielded a 27% increase in overall
response rates compared with fluorouracil plus cisplatin-based
chemotherapy alone [41]. This virus was approved by Chinese
State Food and Drug Administration for the treatment of late-
stage refractory nasopharyngeal cancer.
Here, to improve tumor specificity and reduce toxicity for
normal cells, we developed a novel CRAd whose replication
was controlled by miR-199. The use of miRNA target (miRT)
sequences was first described by Naldini and colleagues to
specifically modulate transgene expression in hematopoietic
cells [42] or hepatocytes [43]. The present work is the first that
make use of miR-199 to target an oncolytic virus to cancer cells
in vivo. Other works have employed miRNAs to reduce viral
pathogenicity in normal tissues [44,45]. Kelly et al. could
restrict replication of an oncolytic coxsackievirus (CVA21) to
reduce its replication in normal muscle tissue and thus reduce
muscle inflammation without compromising tumor cell-killing
ability [46]. Fu and colleagues constructed a LCSOV (liver-
cancer-specific oncolytic virus) in which the essential viral
glycoprotein H gene (gH gene) was controlled by both an
apoE-AAT liver-specific promoter and the presence of
complementary sequences to miR-122, miR-124a and let-7a in
its 3’ UTR [47]. Using that strategy they were able to generate
an oncolytic virus able to kill HCC cells in a xenograft model.
The Ad-199T virus was designed to replicate in miR-199-
negative cells. This objective was achieved by introducing into
the viral genome multiple miR-199 target sites able to modulate
the expression of the E1A gene. Since virtually 100% HCCs
exhibit a strong down-regulation of miR-199 which is instead
expressed at substantial level in normal hepatocytes, where it
Figure 4.  miR-199 controls Ad-199T replication in vivo.  To assess replication properties of AD-199T in vivo, 1x108 I.U. of
Ad-199T or 1x108 I.U. of Ad-Control were intra-hepatically injected into 3 days old B6D2 mice. At 72 hours after infection, livers were
collected and viral DNA quantified using analytical PCR (A) and quantitative PCR as fold change copies of Adeno DNA referred to
the lower level of Adenovirus DNA copies (B) The replication of Ad-199T (mice 1375, 1376) was significantly suppressed in normal
liver comparing with Ad-Control (mice 1370, 1372). This evidence confirms that miR-199 could control Ad-199T replication in normal
liver cells in vivo.
doi: 10.1371/journal.pone.0073964.g004
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Figure 5.  Ad-199T replicates in tumor cells in vivo.  (A) 2x106 HepLuc cells were intra-hepatically implanted in B6D2 wild type
mice at 3 days of birth and examined at the In Vivo Imaging System (IVIS) two hours after cells implantation. After 24 hours, three
experimental groups, consisting of six mice each, were defined: one was injected intra-hepatically with 1x108 I.U. of the Ad-199T
virus; one was infected with 1x108 I.U. of the Ad-Control virus; one was not infected (no virus). Mice were monitored at the IVIS at
24h (B), 48h (C) and 72h (D) after virus inoculation. Reduction in pseudo-color images, representing bioluminescence intensity,
indicates that the implanted tumor cells were eliminated, likely due to the active viral replication by either Ad-Control or Ad-199T
viruses. (E) A quantitative photon analysis of the region-of-interest showed a highly significant decrease (p value <0.05) of
luminescence in mice infected with Ad-Control and Ad-199T viruses versus uninfected animals.
doi: 10.1371/journal.pone.0073964.g005
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represents the third most highly expressed miRNA [48], this
virus was designed to prevent cytolytic activity in healthy cells,
thereby addressing the important issue of a novel therapeutic
approach with improved efficacy and safety in HCC.
By investigating in vitro and in vivo properties of Ad-199T, we
demonstrated that this CRAd could replicate very poorly in cells
expressing miR-199, while its replication could proceed
regularly in cells lacking the expression of this miRNA. Since
miR-199 is highly expressed in normal liver, but not in HCC,
this virus seems to be well suited for the treatment of liver
cancer. By testing various experimental in vivo models, we
confirmed this potential opportunity. First, in 3 days old mice,
which have a limited or absent immune response [49], Ad-199T
was not able to replicate in the liver while an identical control
virus, lacking the miR-199 target sites, could efficiently undergo
several rounds of replication. In this model, control adenovirus,
but not Ad-199T, induced an evident hepatoxicity, as
evidenced by histological and immunohistochemical analyses.
This foreseeable finding was a consequence of the inhibitory
effect imposed by miR-199 on Ad-199T replication, thereby
preventing its lytic activity in healthy cells. This property is
shared with other recently developed miRNA-dependent
oncolytic adenoviruses, like
miR-122-based adenovirus-detargeting vectors, which
exhibited a reduced virus-related liver toxicity [9,50,51,52,53].
However, miR-122 is a liver-specific miRNA and is not
expressed in any other tissue, leaving open the possibility that
toxicities due to viral replication could eventually affect other
tissues. Since miR-199 is instead expressed at variable but
significant level in any normal tissues, Ad-199T could lack
toxicity in tissues other than liver as well.
To support the anti-tumor oncolytic activity of Ad-199T, we
proved that the virus could slow-down the growth of xenografts
made of liver cancer cells subcutaneously implanted into nude
mice. Also in this model, the reduced viral toxicity was
supported by the fact that all treated immune deficient mice
could survive following 6 consecutive administrations of large
amounts of replication-competent viruses. As found with other
oncolytic adenoviruses, Ad-199T did not cause tumor
regression, but the anti-tumor effect was significant. As
previously mentioned, it is possible that this virus, like other
CRAds, could find its best use to boost efficacy of chemo or
radiotherapy.
We also investigated the anti-tumor effect in an immune-
competent host mouse model, highly susceptible to the
development of liver primary tumors. Administration of Ad-199T
induced a significant reduction of the number and size of tumor
nodules, most likely because Ad-199T could replicate more
efficiently in neoplastic than in normal liver cells. A conceptually
similar but different oncolytic virus was developed by Jin et al.
It was engineered as a let-7 dependent oncolytic adenovirus,
able to replicate only in cells lacking the let-7 miRNA. The
authors specify that let-7 is down-regulated in about 36% of
HCC, thereby suggesting that this virus could produce a
potential therapeutic effect in this subset of HCCs [54].
Together with the studies on miR-122 and let-7, the present
study indicates that the knowledge of miRNA expression levels
in normal and cancer cells may be applied to the design of
Figure 6.  Differential replication of Ad-199T in normal liver versus tumor cells.  2x106 HepLuc cells were intra-hepatically
implanted in six B6D2 wild type mice 3 days after birth. After 24 hours, the animals were injected intra-hepatically with 1x108 I.U. of
the Ad-199T virus. Mice were sacrificed at 24h and 48h after the treatment and livers as well as tumor cells masses were collected.
Genomic DNA extracted both from normal liver and tumor masses was analyzed by analytical PCR (A) and quantitative PCR as fold
change copies of Adeno DNA referred to the lower level of Adenovirus DNA copies (B). The results show a significant suppression
of Ad-199T replication in normal liver (NL) compared to tumors (Tumor). P-values of the comparisons are shown.
doi: 10.1371/journal.pone.0073964.g006
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oncolytic viruses that combine selective efficacy against cancer
cells with minimal adverse toxic effects.
Figure 7.  Ad-199T antitumor activity on HCC xenograft.  CD1 nude mice (n=6) bearing Hep3B xenografts were treated intra-
tumorally either with PBS or with Ad-199T (5x108 I.U. each treatment, for a total of six). (A) A tumor growth curve was built by
measuring the size of tumors every two days. The results shown a significant difference between the PBS-treated group and the
Ad-199T-treated one (p=0.001), confirming the antitumor activity of Ad-199T virus. (B) Kaplan-Meier survival plot showed a median
survival of 24 days for untreated animals and 45 days for Ad-199T treated animals, thus indicating a longer survival time in animals
treated with the oncolytic adenovirus. This difference was highly significant according to the log-rank test (p <0.0001).
doi: 10.1371/journal.pone.0073964.g007
miR-199-Dependent Oncolytic Adenovirus
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e73964
Figure 8.  Ad-199T therapeutic activity against DENA-induced tumors in HCC mouse model.  A group of TG221 transgenic
male mice was treated intra-peritoneum with the carcinogen DEN to boost the development of liver tumors. Three experimental
groups, consisting of four mice each, were then defined: the first group was infected two times, at day 60 and 135 after DEN
treatment, with 1x108 I.U. of Ad-199T virus, through tail vein injection; the second group was infected with the Ad-Null-Control non-
replicative adenovirus (Ad NR), at the same time points with the same I.U; the third group was the not infected control group. All the
mice were sacrificed at five months of age and livers collected. (A-B) Macroscopically, tumors appeared to be less and smaller in
mice treated with the Ad-199T virus in comparison with mice either untreated or treated with Ad NR. Quantitative parameters
confirmed the qualitative observations. (C) Tumor burden was reduced in Ad-199T treated mice as shown by the significant
reduction of liver weights. (D) The number of tumor nodules was also significantly lower in mice treated with Ad-199T in comparison
with the control animals. (E) RNAs from normal livers and tumors were analyzed by Real-Time PCR to assess miR-199 levels: as
expected tumors displayed a lower expression of miR-199. (F) The level of Ad-199T DNA was examined by quantitative Real-Time
PCR in normal liver biopsies and tumor nodules of treated mice: a 2-3 fold increase levels in tumor tissues was detected.
doi: 10.1371/journal.pone.0073964.g008
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Supporting Information
Figure S1.  miR-199 directly interacts with its target
sequence cloned in the pGL3/199T vector, as evaluated by
luciferase activity in Hep3B cells.  The Firefly Luciferase
reporter activity was significantly decreased when pGL3/199T
vector was co-transfected with the pre-miR-199a-3p miRNA
precursor (p value = 0.007). On the contrary, luciferase activity
at the pGL3/199T vector was not significantly affected by a
control scramble oligonucleotide. Basal luciferase activity of the
pGL3/199T vector is also shown. Untransfected Hep3B cells
are indicated as NT. Firefly luciferase activity was normalized
on Renilla Luciferase activity of the co-transfected pRL-TK
vector. Each sample was analyzed in triplicate.
(TIF)
Figure S2.  Scheme of Ad-Control and Ad-199T vectors
construction.  pShuttle/K was the source of E1A/E1B
segment, which was joined to the segments IRES (Internal
Ribosomal Entry Site) EGFP (Enhanced Green Fluorescent
Protein) into the entry vector pENTR11 (Invitrogen) to generate
pENTR_E1A/E1B. This latter vector was used as recipient of
the miR-199 targeting site (199T) into the MluI restriction site,
to generate the pENTR_E1A/199T/E1B vector. Complete
adenovirus genomes were produced by site-specific
recombination of each entry vector with the destination vector
pAd-CMV-V5-Dest (Invitrogen).
(TIF)
Figure S3.  HepG2/199 cell line stably express
miR-199.  The pIRES-miR199 vector, expressing miR-199,
was stably transfected in the hepatocellular carcinoma derived
cell line HepG2, generating the HepG2/199 cell line. TaqMan,
Real Time PCR analysis showed that miR-199 expression was
significantly increased in the HepG2/199 cell line in comparison
with the basal expression level in the HepG2 cells (p-value =
0.0005) and not significantly different from human normal liver
(NL) expression levels (p-value = 0.06). Each sample was
analyzed in triplicate.
(TIF)
Figure S4.  Histopathology and phospho-H2AX staining in
livers infected with Ad-Control or Ad-199T.  (A) In Ad-
Control infected livers, macro-vesicular steatosis associated
with disruption of the normal liver architecture can be seen;
nuclei are displaced at the edge of the cells by the large fat
vacuoles. (B) Another feature seen in Ad-Control infected livers
was the accumulation of micro-vesicles in the cytoplasm of
hepatocytes, which were variable in size with heterogeneous
nuclei. (C) These histopathology changes were nearly absent
in the livers of Ad-199T treated mice. Cell plate structure was
conserved, hepatocyte cytoplasm was not generally vacuolated
and nuclei showed a very little polymorphism. (D) The livers
from control mice exhibited very few hepatocytes that stained
positive for phospho-H2AX (red arrows). A very faint staining
was observed in the nuclei of endothelial cells surrounding
hepatic veins (orange arrows). (E) Few hepatocytes with
apoptotic appearance stained positive for phospho-H2AX (red
arrows). In spite of the absence of histopathological changes,
some hepatocytes exhibited a faint nuclear staining for
phospho-H2AX (blue arrows). (F) Livers infected with Ad-
Control displayed a nearly ubiquitous IHC staining for phospho-
H2AX, detectable in the nuclei of hepatocytes, of endothelial
cells and of bile ducts. Apoptotic hepatocytes in the context of
necrotic areas show an intense staining for phospho-H2AX (red
arrows).
(TIF)
Figure S5.  HepLuc cell line stably express Luciferase
gene.  HepG2 cell line was stably transfected with pIRES-Luc,
a vector expressing the Luciferase reporter gene under the
control of a CMV promoter. Several HepLuc stable clones were
obtained and the reporter gene expression was tested by a
Luciferase assay. Each sample was analyzed in triplicate.
(TIF)
Figure S6.  Ad-199T and Ad-Control can eliminate
implanted tumor cells in vivo.  Treated animals described in
Figure 5 were sacrificed 72 hours after virus injection and the
livers were collected (A-C). Images of the livers showed the
presence of tumor masses corresponding to luminescent signal
detected at the IVIS luminometer. Tumor masses were larger in
uninfected controls and significantly reduced in mice treated
with both Ad-199T and Ad-Control viruses.
(TIF)
Figure S7.  Evidence of human genomic DNA in mice
tumor masses.  Genomic DNA was extracted both from
normal livers (NL) and tumor masses (Tumor) of mice injected
intra-hepatically with HepLuc cells and treated with Ad-199T
virus. The mice were sacrificed after 24 and 48 hours. All the
samples were analyzed by analytical PCR using primers for the
human TPEF (transmembrane protein containing epidermal
growth factor and follistatin domain) gene. As housekeeping
gene, specific primers for mouse β-actin were used. As a
negative control (-), mouse tail genomic DNA was used. As a
positive control (+), HepG2 genomic DNA was used.
(TIF)
Figure S8.  Tumor cell removal is triggered by viral lytic
cycle as well as immune response to viral antigens.  (A)
1x106 HepLuc cells were intra-hepatically implanted into B6D2
wild type mice at 3 days of age. Two hours after cells
implantation, mice were examined at the In Vivo Imaging
System (IVIS) to verify homogeneity among the various
implants. Bioluminescence intensity, measured as luciferase
activity is shown as pseudo-color images and is proportional to
the amount of tumor cells. The day after, three experimental
groups, consisting of six mice each, were defined: one was
intra-hepatically injected with 1x108 I.U. of the Ad-199T virus;
the second with 1x108 I.U. of a not replicative adenovirus (Ad-
NR); the third received no virus. Mice were then monitored at
24h (B), 48h (C) and 72h (D) after virus injection. (E) Faster
reduction of implanted tumor cells was detected in the Ad-199T
virus group than in the not replicative adenovirus or the no
virus group. Quantitative photon analysis showed a significant
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difference (24h, p value = 0.0008; 48h, p value = 0.025; 72h, p
value = 0.022) of luminescence in mice treated with Ad-199T
versus mice treated with a replicative-defective adenovirus.
The difference between the no virus and the not replicative
adenovirus groups was significant at 48h and 72h.
(TIF)
Figure S9.  Ad-199T replicates in Hep3B cell line.  (A) To
asses miR-199 expression levels in Hep3B cell line, a TaqMan,
Real Time PCR was performed. The results showed that
Hep3B displayed a very low basal miR-199 expression level,
even lower than HepG2 cells. Each sample was analyzed in
triplicate. (B-C) To verify miR-199-depentent replication
capability of Ad-199T virus in Hep3B cells, cells were seeded
and infected with 1x106 I.U of Ad-199T and harvested after 24,
48, 72, 96 and 120hrs. Genomic DNAs extracted were
analyzed by analytical and quantitative PCR as a fold change
copies of Adeno DNA referred to the lower level of Adenovirus
copies.
(TIF)
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